China coronavirus

China is keeping its vaccination campaign homegrown -- despite some reservations from the public.

The rationale (and danger) of China’s lack of direct financial support to the people during the pandemic.

Despite cooperating on some aspects, China and Russia are also directly competing for the same vaccine markets - and the national prestige that comes with it.

The COVID-19 crisis pushed to the frontlines a civil society that is mobilized and led by the Chinese Communist Party, whether directly or indirectly.

The WHO team's activities will be closely watched -- figuratively by the world, and literally by the Chinese government.

A government-sanctioned look back at the early fight against COVID-19 differs sharply from a documentary directed by artist and dissident Ai Weiwei.

As a global team arrives to investigate the pandemic’s origins, China is seeing a rare surge in its infections.

With its first homegrown vaccine approved for general use, China aims to vaccinate 50 million people by the Lunar New Year in February.

Earlier this week, the WHO head expressed his disappointment at a “last minute” halt to a planned experts’ visit.

China’s government is only allowing hand-picked research teams to look into the origins of COVID-19 – and keeping tight control over any findings.

The UAE has officially approved a Sinopharm vaccine, while there are promising unofficial results from Sinovac’s Indonesia trial.

China’s new focus on testing packaging comes amid a media push to claim that frozen food imports brought the virus to Wuhan in the first place.